BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14750178)

  • 21. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor.
    Pilon SA; Kelly C; Wei WZ
    J Immunol; 2003 Feb; 170(3):1202-8. PubMed ID: 12538677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.
    Chen Y; Hu D; Eling DJ; Robbins J; Kipps TJ
    Cancer Res; 1998 May; 58(9):1965-71. PubMed ID: 9581840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.
    Romieu-Mourez R; François M; Abate A; Boivin MN; Birman E; Bailey D; Bramson JL; Forner K; Young YK; Medin JA; Galipeau J
    Cancer Res; 2010 Oct; 70(20):7742-7. PubMed ID: 20924101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
    Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model.
    Nguyen-Hoai T; Baldenhofer G; Ahmed MS; Pham-Duc M; Gries M; Lipp M; Dörken B; Pezzutto A; Westermann J
    J Gene Med; 2012 Feb; 14(2):128-37. PubMed ID: 22228591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys.
    Ko HJ; Kim YJ; Kim YS; Kim JM; Ho SH; Jeong JG; Oh SM; Chae JA; Kim CY; Lee PS; Kang CY
    Gene Ther; 2008 Oct; 15(20):1351-60. PubMed ID: 18480847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
    Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging.
    Provinciali M; Barucca A; Pierpaoli E; Orlando F; Pierpaoli S; Smorlesi A
    Cancer Immunol Immunother; 2012 Mar; 61(3):363-71. PubMed ID: 21922332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.
    Curcio C; Di Carlo E; Clynes R; Smyth MJ; Boggio K; Quaglino E; Spadaro M; Colombo MP; Amici A; Lollini PL; Musiani P; Forni G
    J Clin Invest; 2003 Apr; 111(8):1161-70. PubMed ID: 12697735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
    Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
    Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
    Park JM; Terabe M; Steel JC; Forni G; Sakai Y; Morris JC; Berzofsky JA
    Cancer Res; 2008 Mar; 68(6):1979-87. PubMed ID: 18339880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice.
    Wei WZ; Jacob JB; Zielinski JF; Flynn JC; Shim KD; Alsharabi G; Giraldo AA; Kong YC
    Cancer Res; 2005 Sep; 65(18):8471-8. PubMed ID: 16166327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
    Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
    Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML; Grabstein KH; Sleath PR; Cheever MA
    Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
    Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ
    Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.